Australia's most trusted
source of pharma news
Wednesday, 16 July 2025
Posted 29 October 2024 AM
The Medical Services Advisory Committee (MSAC) has deferred its advice on public funding for a lutetium-based radiopharmaceutical likened to Novartis' Lutathera, raising concerns about the data presented.
Homegrown radiopharmaceuticals manufacturer Applied Molecular Therapies (AMT) applied for 177Lutetium(nca) Octreotate to be listed on the MBS for the treatment of advanced neuroendocrine (NET) and other high somatostatin receptor expressing (H-SSTR) cancers.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.